Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB)

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is among the 12 Best Genomics Stocks to Invest In.

On December 15, TheFly published that Luke Sergott, a Barclays analyst, lifted the price objective for Pacific Biosciences of California, Inc. (NASDAQ:PACB) from $1.50 to $2 and maintained an Equal Weight rating for the shares. As part of its 2026 forecast, the company modified price objectives and ratings in the life sciences and diagnostics tools area. The analyst informs investors in a research note that the final estimate cuts, improving end markets, and the fact that tools are the most undervalued space in healthcare offer a very favorable backdrop for the tools group to beat the market in 2026.

Separately, last quarter’s revenue came in slightly less than the company’s projections, at $38.4 million, mainly due to fewer than expected Vega sales in Europe and lower than anticipated revenue on ASPs.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) anticipates an improvement in the fourth quarter with sequential revenue growth of about 10%. The company noted that revenue growth will be driven by higher Revio placements and the sustained strength in consumables observed throughout the year. It reduced sales projections for the entire year 2025 to a range of $155 million to $160 million.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) creates innovative DNA sequencing technology to aid researchers in better understanding complex genomes.

While we acknowledge the potential of PACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None